Immatics (IMTX) Metrics: History & Chart

Immatics N.V.(IMTX)

Biotechnology · Tübingen, BW

$7.53-0.20 (-2.59%)

Delayed quote: Oct 6, 2026, 10:10 AM EDT

About Immatics N.V.

Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.

Tübingen, BW

704 employees

www.immatics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Harpreet Singh

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-9.06%
30D Total Return	-19.14%
YTD Total Return	-26.38%
1Y Total Return	-17.77%
3Y Total Return	-20.47%
5Y Total Return	-40.55%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	-26.38%
2025	+47.68%
2024	-32.48%
2023	+20.90%
2022	-35.19%
2021	+24.56%
2020

CAGR TTM	-17.69%
CAGR 3Y	-7.35%
CAGR 5Y	-9.88%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	31.13
PE Ratio Avg TTM	31.31
PE Ratio Avg 3Y	22.45
Current VS TTM Avg	-0.58%
Current VS 3Y Avg	+38.67%
Current VS 5Y Avg	+38.67%

All Metrics

IMTX Valuation Metrics

IMTX Stock Price Metrics

IMTX Dividend Metrics

IMTX Growth Rate Metrics

IMTX Discounted Cash Flow Metrics

IMTX Returns By Period

IMTX Yearly Returns

IMTX Average Annual Returns By Period (CAGR)

IMTX Revenue Metrics

IMTX PE Ratio Metrics

IMTX PS Ratio Metrics

IMTX PB Ratio Metrics

IMTX Price to Free Cash Flow Ratio Metrics

IMTX Debt to Equity Ratio Metrics

IMTX PEG Ratio Metrics

IMTX FCF Yield

IMTX Earnings Yield

IMTX EBITDA Yield

IMTX OCF Yield

IMTX EV/EBIT Ratio Metrics

IMTX EV/EBITDA Ratio Metrics

IMTX EV/Assets Ratio Metrics

IMTX EV/Sales Ratio Metrics

IMTX Current Ratio Metrics

IMTX Quick Ratio Metrics

IMTX ROIC Metrics

IMTX Return on Assets Metrics

IMTX Return on Equity Metrics

IMTX Net Profit Margin Metrics

IMTX Gross Profit Margin Metrics

IMTX Tax Rate Metrics

PS Ratio	21.77
PS Ratio Avg TTM	20.87
PS Ratio Avg 3Y	12.69
Current VS TTM Avg	+4.31%
Current VS 3Y Avg	+71.51%
Current VS 5Y Avg	+87.02%

PB Ratio	2.32
PB Ratio Avg TTM	2.45
PB Ratio Avg 3Y	2.38
Current VS TTM Avg	-5.18%
Current VS 3Y Avg	-2.35%
Current VS 5Y Avg	-24.25%

PFCF Ratio	6.97
PFCF Ratio Avg TTM	5.55
PFCF Ratio Avg 3Y	5.81
Current VS TTM Avg	+25.66%
Current VS 3Y Avg	+19.96%
Current VS 5Y Avg	-41.96%

Debt/Equity Ratio	0.04
Debt/Equity Ratio Avg TTM	0.04
Debt/Equity Ratio Avg 3Y	0.04
Current VS TTM Avg	+2.62%
Current VS 3Y Avg	+0.45%
Current VS 5Y Avg	-40.59%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	14.35%
FCF Yield Avg TTM	18.34%
FCF Yield Avg 3Y	16.88%
Current VS TTM Avg	-21.76%
Current VS 3Y Avg	-15.01%
Current VS 5Y Avg	+33.56%

Earnings Yield	3.21%
Earnings Yield Avg TTM	3.17%
Earnings Yield Avg 3Y	5.54%
Current VS TTM Avg	+1.12%
Current VS 3Y Avg	-42.01%
Current VS 5Y Avg	-42.01%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	16.20
Ev/Ebit Ratio Avg TTM	24.63
Ev/Ebit Ratio Avg 3Y	24.63
Current VS TTM Avg	-34.23%
Current VS 3Y Avg	-34.23%
Current VS 5Y Avg	-34.23%

Ev/Ebitda Ratio	13.52
Ev/Ebitda Ratio Avg TTM	19.57
Ev/Ebitda Ratio Avg 3Y	19.57
Current VS TTM Avg	-30.91%
Current VS 3Y Avg	-30.91%
Current VS 5Y Avg	-30.91%

Ev/Assets Ratio	1.46
Ev/Assets Ratio Avg TTM	1.48
Ev/Assets Ratio Avg 3Y	1.27
Current VS TTM Avg	-1.32%
Current VS 3Y Avg	+14.66%
Current VS 5Y Avg	+6.36%

Ev/Sales Ratio	16.64
Ev/Sales Ratio Avg TTM	15.40
Ev/Sales Ratio Avg 3Y	10.40
Current VS TTM Avg	+8.09%
Current VS 3Y Avg	+59.94%
Current VS 5Y Avg	+82.67%

Current Ratio	7.54
Current Ratio Avg TTM	8.84
Current Ratio Avg 3Y	6.49
Current VS TTM Avg	-14.73%
Current VS 3Y Avg	+16.11%
Current VS 5Y Avg	+49.69%

Quick Ratio	7.54
Quick Ratio Avg TTM	8.84
Quick Ratio Avg 3Y	6.48
Current VS TTM Avg	-14.73%
Current VS 3Y Avg	+16.33%
Current VS 5Y Avg	+50.17%

ROIC	(53.36%)
ROIC Avg 3Y	(22.27%)
ROIC Avg 5Y	(19.92%)
Current VS 3Y Avg	-139.66%
Current VS 5Y Avg	-167.86%
Current VS 10Y Avg	-64.99%

ROA	(43.17%)
ROA Avg TTM	(10.40%)
ROA Avg 3Y	(5.66%)
Current VS TTM Avg	-315.12%
Current VS 3Y Avg	-662.06%
Current VS 5Y Avg	-577.95%

ROE	(52.47%)
ROE Avg TTM	(36.94%)
ROE Avg 3Y	(27.12%)
Current VS TTM Avg	-42.02%
Current VS 3Y Avg	-93.45%
Current VS 5Y Avg	-218.82%

Net Profit Margin	(493.26%)
Net Profit Margin Avg TTM	(816.62%)
Net Profit Margin Avg 3Y	(389.19%)
Current VS TTM Avg	+39.60%
Current VS 3Y Avg	-26.74%
Current VS 5Y Avg	-97.76%

Gross Profit Margin	100.00%
Gross Pft Margin Avg TTM	100.00%
Gross Pft Margin Avg 3Y	100.00%
Current VS TTM Avg	0.00%
Current VS 3Y Avg	0.00%
Current VS 5Y Avg	+216.19%

Tax Rate	(3.68%)
Tax Rate Avg 3Y	(1.84%)
Tax Rate Avg 5Y	(1.84%)
Current VS 3Y Avg	-100.00%
Current VS 5Y Avg	-100.00%
Current VS 10Y Avg	-100.00%